Ovulation inducing agents and cancer risk: review of literature

Gianna Gabriella Impicciatore1, Gian Mario Tiboni

  • 1Sezione di Scienze della Riproduzione, Dipartimento di Medicina e Scienze dell’Invecchiamento, Facoltà di Medicina e Chirurgia, Università G. d'Annunzio Chieti-Pescara, Italy.

Current Drug Safety
|December 2, 2011
PubMed

Insights

Fertility drugs like clomiphene citrate may not increase cancer risk, despite early concerns. More research is needed to confirm findings on ovulation induction and malignancy associations.

Area of Science:

  • Reproductive Medicine
  • Oncology
  • Epidemiology

Background:

  • The use of ovulation-inducing drugs has risen, prompting investigation into potential links with various cancers.
  • Concerns exist regarding fertility treatments, including clomiphene citrate and gonadotropins, and their association with malignancies.
  • Existing studies often have methodological limitations, such as small sample sizes and incomplete follow-up.

Purpose of the Study:

  • To evaluate the potential causal link between fertility treatments and cancer risk.
  • To synthesize current evidence regarding ovulation-inducing agents and specific malignancies.
  • To address the methodological shortcomings of previous research in this field.

Main Methods:

  • Review and analysis of existing epidemiological studies on fertility drugs and cancer.
  • Assessment of data quality, including sample size, follow-up duration, and control for confounders.
  • Comparative analysis of findings across different cancer types and fertility treatments.

Main Results:

  • The majority of evidence does not support a causal link between ovulation-inducing agents and ovarian cancer.
  • Increased cancer risk observed after in vitro fertilization (IVF) appears related to infertility itself, not the treatment drugs.
  • Evidence regarding breast cancer risk associated with clomiphene citrate is controversial and inconclusive.
  • Some studies suggest a potential trend towards increased endometrial cancer risk, warranting further investigation.

Conclusions:

  • Current data on fertility drugs and cancer risk are not definitive and signal the need for more robust research.
  • Methodological limitations in existing studies hinder conclusive statements about malignancy risks.
  • Further well-designed studies are essential to clarify the relationship between ovulation induction and cancer development.

Related Concept Videos

Cancer Prevention02:59

Cancer Prevention

Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Cancer Prevention02:59

Cancer Prevention

Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Hormonal Control of the Ovarian Cycle01:30

Hormonal Control of the Ovarian Cycle

The ovarian cycle is meticulously regulated by the hypothalamic-pituitary-gonadal axis. This cycle orchestrates the release of a mature oocyte, essential for reproduction.
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle.  At puberty, GnRH secretion increases in both frequency and...
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...